{"id":151311,"date":"2026-08-24T09:54:29","date_gmt":"2026-08-24T09:54:29","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/151311\/"},"modified":"2026-08-24T09:54:29","modified_gmt":"2026-08-24T09:54:29","slug":"lilly-novo-amp-up-glp-1-fight-with-new-weapon-against-copycats-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/151311\/","title":{"rendered":"Lilly, Novo Amp Up GLP-1 Fight With New Weapon Against Copycats"},"content":{"rendered":"<p>Eli Lilly &amp; Co. and Novo Nordisk A\/S are leveraging a fresh weapon in their crackdown against copycat versions of their blockbuster weight loss drugs.<\/p>\n<p>The two pharmaceutical giants over the last year have filed 10 cases against compounders and telehealth companies with BBB National Programs\u2019 National Advertising Division, a self-regulatory body providing dispute resolution over advertising claims. The non-government group has been around since 1971, <a href=\"https:\/\/bbbprograms.org\/media\/newsroom\/decisions\" rel=\"nofollow noopener\" target=\"_blank\">settling disagreements<\/a> over products from bathroom cleaners to infant formula \u2014 but the GLP-1 drugmakers turned to it relatively recently.<\/p>\n<p>It\u2019s another avenue in the aggressive fight to rein in unapproved versions of their &#8230;<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly &amp; Co. and Novo Nordisk A\/S are leveraging a fresh weapon in their crackdown against copycat&hellip;\n","protected":false},"author":2,"featured_media":151312,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[272,3588,64656,2338,1446,360],"class_list":["post-151311","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-novo-nordisk","tag-online-advertising","tag-pharmaceutical-advertising","tag-settlements","tag-social-media","tag-telehealth"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117149883785736553","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/151311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=151311"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/151311\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/151312"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=151311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=151311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=151311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}